What's new? Log in Free sign up

Filing search / Pulmatrix, Inc. / "Strategy"

Search information

Pulmatrix, Inc.

Companies

"Strategy"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

56 results

Newest first Best match first

PULM Pulmatrix, Inc.

Shelf registration

that may give rise to a change in the use of proceeds include: a change in business plan or strategy; the addition of new products or applications … business collaborations or other sales or licensing of assets, the amount of competition, a change in business plan or strategy, our ability to select

17 May 24

4:06pm

PULM Pulmatrix, Inc.

in 2013 as a Delaware corporation. Business Strategy Our goal is to develop breakthrough therapeutic products that are safe, convenient, and more … additional drug candidates or approved drug products could impair our ability to grow. As part of our growth strategy, we may evaluate, acquire

28 Mar 24

9:21am

PULM Pulmatrix, Inc.

Definitive proxy

. The Audit Committee and the full Board focus on the most significant risks facing the Company and the Company’s general risk management strategy

2 Jun 23

9:20am

PULM Pulmatrix, Inc.

and tolerability profiles. We were incorporated in 2013 as a Delaware corporation. Business Strategy Our goal is to develop breakthrough therapeutic … , develop and market additional drug candidates or approved drug products could impair our ability to grow. As part of our growth strategy, we may

30 Mar 23

9:20am

PULM Pulmatrix, Inc.

Definitive proxy

management strategy. In addition, as part of its oversight of our Company’s executive compensation program, the Compensation Committee considers

29 Apr 22

4:06pm

Departure of Directors or Certain Officers

29 Mar 22

9:20am

xqm4dgldzdsty yaki

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

yfp67xhq68nm3xvhs4n

Prospectus supplement for primary offering

s9qhwe8pjv07z9juqt51

Departure of Directors or Certain Officers

rtt31jc 5rqmuyi6uxv

Shelf registration

26 May 21

5:05pm

Definitive proxy

29 Apr 21

9:05am

23 Mar 21

9:20am

Prospectus supplement for primary offering

2zg3qr8rmlznarnde

Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates

nplii k5ut43ust7

Pulmatrix Reports Q2 2020 Results and Business Updates

96txgpn51iloz xts

Definitive proxy

29 Apr 20

9:01am

Prospectus supplement for primary offering

16lq0yqmh6 d6gwhkb

Entry into a Material Definitive Agreement

0ze05c0b2qxagit

26 Mar 20

9:22am

Prev
1
2
3
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.